GSK is forecasted to report a third quarter revenue of £8.82 billion, slightly below consensus, with core earnings per share matching expectations. Weak vaccine sales, particularly Shingrix, are expected to be offset by stronger performance in HIV treatments like Cabenuva and respiratory drug Nucala. The company may narrow its full-year guidance and focus on cost savings and pipeline developments. Key upcoming events include a US regulatory decision on hepatitis B treatment and an oncology update in late October.
As of Oct 13, 2026 16:51 WIB, GSK shares trade at USD 47.31 on Pluang, up 0.83% for the day but still below their 52-week high of USD 61.18. The stock's dividend yield stands at 3.91%, attracting mostly buyers with 89% of order activity favoring purchases. This positions GSK in a recovery phase after dipping closer to its 52-week low of USD 43.24, reflecting cautious optimism among investors.
